hims & hers fda warning letter compounded semaglutide 2025 Health (HIMS) Securities Class Action Lawsuit Update From Crackdown to Collaboration: FDA

The Bottom Line In under two decades, GLP-1 agonists moved from niche diabetes drugs to pillars of cardiometabolic carelowering glucose, reducing weight, and, as SELECT showed, preventing heart attacks

What distinguishes retatrutide from its predecessors is the inclusion of glucagon receptor agonism

The FDA approved semaglutide for weight management in 2021 under the brand name Wegovy, while tirzepatide received approval in 2022 under the brand name Zepbound

The Remaining Gaps in Employer-Covered GLP-1 Benefits Mike Hollan , Susan Thomas Susan Thomas, chief commercial officer at LucyRx, explains the areas where GLP-1 coverage still lacks

Insurance Coverage Considerations Prior Authorization Requirements Trying to figure out if Ambetter foots the bill for weight loss meds